nach oben

Erschienen in:

04.01.2020 | Original Paper

“Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication

verfasst von: Ilona Fridman, Peter A. Ubel, Jennifer Blumenthal-Barby, Cameron V. England, Judith S. Currier, Nir Eyal, Kenneth A. Freedberg, Scott D. Halpern, Colleen F. Kelley, Daniel R. Kuritzkes, Catherine N. Le, Jeffrey L. Lennox, Kathryn I. Pollak, Brian J. Zikmund-Fisher, Karen A. Scherr

Erschienen in: AIDS and Behavior | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Abstract

Many people living with HIV (PLWHIV) state that they would be willing to take significant risks to be “cured” of the virus. However, how they interpret the word “cure” in this context is not clear. We used a randomized survey to examine whether PLWHIV had a different willingness to take a hypothetical HIV medication if it causes flu-like symptoms, but provides: (a) cure, (b) remission that was labeled “cure”, or (c) remission. PLWHIV (n = 454) were more willing to take a medication that provided a “cure” versus a “remission” if the side effects lasted less than 1 year. PLWHIV were more willing to take a medication that provided a remission that was labeled “cure” versus a “remission” (p = 0.01) if the side effects lasted 2 weeks. Clinicians and researchers should be aware of the impact of the word “cure” and ensure that PLWHIV fully understand the possible outcomes of their treatment options.

Nur mit Berechtigung zugänglich

Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, Paredes R, Bakowska E, Engsig FN, Phillips A. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. Aids. 2013;27(6):973–9.PubMedCrossRef

van Sighem A, Gras L, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS. 2010;24(10):1527–35.PubMedCrossRef

Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on ART across the globe: comparisons with general population. Curr. Opinion HIVAIDS. 2016;11(5):492–500.CrossRef

Gagnon M. “There is a chain of connections”: using syndemics theory to understand HIV treatment side effects. AIDS Care. 2018;30(7):910–3.PubMedCrossRef

Miners A, Phillips A, Kreif N, Rodger A, Speakman A, Fisher M, et al. Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: a cross-sectional comparison with the general population. Lancet HIV. 2014;1(1):32–40.CrossRef

Wohl DA, Kuwahara RK, Javadi K, Kirby C, Rosen DL, Napravnik S, et al. Financial barriers and lapses in treatment and care of HIV-infected adults in a southern state in the United States. AIDS patient care and STDs. 2017;31(11):463–9.PubMedPubMedCentralCrossRef

Bogart LM, Cowgill BO, Kennedy D, Ryan G, Murphy DA, Elijah J, et al. HIV-related stigma among people with HIV and their families: a qualitative analysis. AIDS Behav. 2008;12(2):244–54.PubMedCrossRef

Murray BR, Kratka A, Scherr KA, Eyal N, Blumenthal-Barby J, Freedberg KA, et al. What risk of death would people take to be cured of HIV and why? A survey of people living with HIV. J. Virus Eradic. 2019;5(2):109–15.

Deeks SG, Lewin SR, Ross AL, Ananworanich J, Benkirane M, Cannon P, et al. International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Med. 2016;22(8):839–50.PubMedCrossRef

10.

Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations). Trend. Mol. Med. 2016;22(1):10–27.CrossRef

11.

FDA. HIV patient-focused drug development backgrounder document. Maryland: FDA; 2013.

12.

International AIDS Society Scientific Working Group on HIV Cure, Deeks SG, Autran B, et al. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 2012;12(8):607–14.CrossRef

13.

Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. Grant P. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244–8.PubMedPubMedCentralCrossRef

14.

Yukl SA, et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 2013;9:e1003347.PubMedPubMedCentralCrossRef

15.

TAG. Research Toward a Cure Trials [Internet]. 2019. http://www.treatmentactiongroup.org/cure/trials. Accessed 30 Aug, 2019.

16.

Dubé K, Luter S, Lesnar B, Newton L, Galea J, Brown B, et al. Use of ‘eradication’ in HIV cure-related research: a public health debate. BMC Pub. Health. 2018;18(1):245–51.CrossRef

17.

Henderson GE. The ethics of HIV “cure” research: what can we learn from consent forms? AIDS Res. Hum. Retrovir. 2015;31(1):56–63.PubMedCrossRef

18.

Peay HL, Henderson GE. What motivates participation in HIV cure trials? A call for real-time assessment to improve informed consent. J. Virus Erad. 2015;1(1):51–3.PubMedPubMedCentral

19.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, et al. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV. 2019;6:259–68.CrossRef

20.

Garner SA, Rennie S, Ananworanich J, Dube K, Margolis DM, Sugarman J, et al. Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations. J. Virus Erad. 2017;3(2):82–4.PubMedPubMedCentral

21.

McMahon JH, Elliott JH, Roney J, Hagenauer M, Lewin SR. Experiences and expectations of participants completing an HIV cure focused clinical trial. AIDS. 2015;29(2):248–50.PubMedPubMedCentralCrossRef

22.

Sylla L, Evans D, Taylor J, Gilbertson A, Palm D, Auerbach JD, et al. If we build it, will they come? Perceptions of HIV cure-related research by people living with HIV in four US cities: a qualitative focus group study. AIDS Res. Hum. Retrovir. 2018;34(1):56–66.PubMedCrossRef

23.

Krishnamurti T, Woloshin S, Schwartz LM, Fischhoff B. A randomized trial testing US Food and Drug Administration “breakthrough” language. JAMA Int. Med. 2015;175(11):1856–8.CrossRef

24.

Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based Hortega study. J. Hypertens. 2003;21(7):1283–9.PubMedCrossRef

25.

Scherer LD, Finan C, Simancek D, Finkelstein JI, Tarini BA. Effect of “pink eye” label on parents’ intent to use antibiotics and perceived contagiousness. Clin. Pediatr. 2016;55(6):543–8.CrossRef

26.

Scherer LD, Zikmund-Fisher BJ, Fagerlin A, Tarini BA. Influence of “GERD” label on parents’ decision to medicate infants. Pediatrics. 2013;131(5):839–45.PubMedPubMedCentralCrossRef

27.

Rennie S, Siedner M, Tucker JD, Moodley K. The ethics of talking about ‘HIV cure’. BMC Med. Ethics. 2015;16(1):18–26.PubMedPubMedCentralCrossRef

28.

Eyal N, Kuritzkes DR. Challenges in clinical trial design for HIV-1 cure research. Lancet. 2013;382(9903):1464–5.PubMedCrossRef

29.

Pankrac J, Klein K, Mann JF. Eradication of HIV-1 latent reservoirs through therapeutic vaccination. AIDS Res. Therapy. 2017;14(1):45–9.CrossRef

Titel: “Cure” Versus “Clinical Remission”: The Impact of a Medication Description on the Willingness of People Living with HIV to Take a Medication
verfasst von: Ilona Fridman
Peter A. Ubel
Jennifer Blumenthal-Barby
Cameron V. England
Judith S. Currier
Nir Eyal
Kenneth A. Freedberg
Scott D. Halpern
Colleen F. Kelley
Daniel R. Kuritzkes
Catherine N. Le
Jeffrey L. Lennox
Kathryn I. Pollak
Brian J. Zikmund-Fisher
Karen A. Scherr
Publikationsdatum: 04.01.2020
Verlag: Springer US
Erschienen in: AIDS and Behavior / Ausgabe 7/2020
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-019-02769-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19

Clinical Care, Research, and Telehealth Services in the Era of Social Distancing to Mitigate COVID-19

Medically, Traditionally, and Dually Circumcised Men in Lesotho: Population-Based Measurements of HIV/STI Infections, Sexual Risk Behaviors, and Service Use Patterns

Neighborhood Poverty and Control of HIV, Hypertension, and Diabetes in the Women’s Interagency HIV Study

COVID-19 and Hidden Housing Vulnerabilities: Implications for Health Equity, New Haven, Connecticut